Skip to content
Search

Latest Stories

'Scrap VAT rate applied to sunscreen products'

Co-op Midcounties has urged the government to exempt sunscreen products from value added tax (VAT).

The consumer co-operative has written to the government to reclassify sunscreen as an essential healthcare item, which would allow it to be VAT exempt.


The average bottle of sunscreen costs between £5 and £7, with around £1.50 VAT charge.

Sunscreen is currently classified in the UK as a “cosmetic product”. However, Cancer Research UK has found that getting sunburnt just once every two years can triple the risk of melanoma skin cancer.

The melanoma skin cancer incidence rates have more than doubled (135 per cent) in the UK since the early 1990s.

Co-op Midcounties Chief Executive Phil Ponsonby said: “Sunscreen is an essential healthcare product and we don’t think it’s right or fair that it should incur VAT. We need to do everything we can to make it as affordable as possible, and we’re therefore asking people to join our campaign, write to their MP and make a change that will help to reduce the risk of skin cancer for everyone.”

Co-op Midcounties expects removing VAT from these essential items will play a significant part in making sunscreen more affordable.

Dr Jones said: “Sunscreen is a really important medical product that prevents against the risk of skin cancer. I fully support the Co-op Midcounties campaign and it’s important that we get Ministers interested in removing VAT from sunscreen. There is a wide consensus of doctors, skin specialists, dermatologists and cancer specialists who would agree that sunscreen should be reclassified as a healthcare product.”

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less